



May 26, 2023

Radiation Safety Committee
Cheyenne Regional Medical Center
NRC License No. 49-01380-01

Committee Members:

To follow up on the 05/01/2023 NRC inspection and the items noted by the inspectors of incomplete Written Directives in Nuclear Medicine, we have implemented the following corrective actions.

1. The Nuc Med Supervisor has updated the NaI-131 Therapy Written Directive to remove items that are unnecessary and to clarify the dosage, route of administration, and the Authorized User signature as required by 10 CFR 35.40.
2. The Nuc Med Supervisor has discarded hard-copies and soft-copies of older Written Directive forms to eliminate a technologist or Authorized User from using an older version for a patient treatment.
3. After each NaI-131 treatment, a second technologists will review the therapy paperwork for completeness before the exam is closed and the paperwork is scanned to PACS.
4. Each quarter, the RSO will review each Written Directive and provide a report to the Radiation Safety Committee at the quarterly meetings.
5. For the Ra-223 Xofigo program, this process is being updated with Radiation Oncology and will be implemented if or when these therapies resume.

If you have any questions regarding this information or wish to provide feedback for improving the radiopharmaceutical therapy program at Cheyenne Regional, please reach out.



Joel McAllister, DABR, CHP
Radiation Safety Officer
joel@centennialmedphys.com
(913) 579-6747